Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
21SEP

Moa raises £22.2m to outrun resistance

3 min read
16:52UTC

Moa Technology, an Oxford Plant Sciences spinout, closed a £22.2m Series C on 23 July after screening more than 900,000 compounds for herbicides that weeds have not yet defeated.

TechnologyDeveloping
Key takeaway

New herbicide chemistry from Oxford reaches farmers through four incumbent agrochemical companies, not through Moa.

Moa Technology, an Oxford Plant Sciences spinout from 2017, closed a £22.2 million Series C on Thursday 23 July co-led by Oxford Science Enterprises and Supernova Invest 1. The company has screened more than 900,000 compounds and found over 80 novel herbicide modes of action. Magdalen College Oxford joined the round alongside GrainInnovate, the Agri Investment Fund and Infinity Investment Partners 2.

A mode of action is the biochemical route by which a chemical kills a plant. Commercial herbicides have leaned on a handful of those routes for decades, weeds have evolved around them, and growers in Australia and the American Midwest are running short of chemistry that still works. Finding a genuinely new route is rare enough that agrochemical majors have gone years without one.

Moa Technology has built no sales force to carry those 80 routes to a field. Its research partnerships run through four incumbent agrochemical companies that already own the distribution and the regulatory teams: Nufarm, Gowan, Certis Belchim and Corteva Agriscience. Moa's chemistry therefore reaches a field on somebody else's sales ledger. Commercialisation is routed through industry here as it is at Humanoid, though this buys a path to market rather than a factory, and none of it is equity.

University spinout deals fell 33% by count last year . A 2017 vintage closing a Series C with Parkwalk and Oxford University Innovation still on the register is what the surviving tail of that pipeline looks like. Agricultural chemistry runs on decade-long timelines: regulatory approval for a new active ingredient takes years after the Science is settled, which is why the survivors are old and the count is falling.

Deep Analysis

In plain English

Moa Technology is a company that grew out of Oxford University's plant science department. Weeds on farms are increasingly resistant to the herbicides farmers already use, in the same way bacteria can become resistant to antibiotics. Moa built software that tests hundreds of thousands of chemical compounds to find new ways to kill resistant weeds that current products cannot. It raised £22.2m to keep developing these, and several big agricultural chemical companies are already working with it to test the most promising candidates.

Deep Analysis
Root Causes

Herbicide resistance evolves because repeated use of the same mode of action selects for the small fraction of a weed population that already carries a resistance mutation; with only a handful of commercial modes of action in wide global use, farmers have had no rotation option broad enough to break that selection pressure, which is the specific gap over 80 new modes of action would need to fill rather than merely adding another product using an existing mechanism.

Discovery of new modes of action stalled industry-wide because large agrochemical companies scaled back internal discovery chemistry after patent cliffs on glyphosate and other blockbusters reduced R&D budgets in the 2000s and 2010s, leaving a gap that a machine-learning screening specialist like Moa, spun out of Oxford Plant Sciences, could enter with lower fixed costs than an incumbent rebuilding a wet-lab discovery programme from scratch.

What could happen next?
  • Opportunity

    A confirmed new mode of action would give UK and global farmers their first genuinely new resistance-management tool in decades, extending the useful life of existing herbicides by allowing rotation.

  • Risk

    None of the 80-plus modes of action Moa reports finding in screening has yet been confirmed in field trials or regulatory filings, so the commercial number that matters, how many reach an approved product, remains unknown.

First Reported In

Update #13 · Humanoid hit $1.35bn on a customer order

PR Newswire· 31 Jul 2026
Read original
Causes and effects
This Event
Moa raises £22.2m to outrun resistance
Moa has found new chemistry but built no sales force, so its route to a field runs through four incumbent agrochemical companies that already own the distribution.
Different Perspectives
Nscale and Open Cosmos
Nscale and Open Cosmos
Nscale chose the New York Stock Exchange for its listing on 18 September, putting Britain's largest AI infrastructure bet to American public investors rather than British ones. Open Cosmos took the opposite route four days earlier, raising nine figures from an all-domestic syndicate on five years of profit, evidence that staying is possible when the balance sheet allows it.
Dame Chi Onwurah and the Science, Innovation and Technology Committee
Dame Chi Onwurah and the Science, Innovation and Technology Committee
Committee chair Dame Chi Onwurah wrote to government on 7 September asking how Matt Clifford's conflict at ARIA arose and what safeguards protect its governance, and expects a detailed response. Her question has not yet been put to the Sovereign AI Unit, whose own chair sits at a venture capital firm while overseeing state AI equity.
The Entrepreneurs Network
The Entrepreneurs Network
The Entrepreneurs Network's founder survey found 65% say Britain is easy to start a business in but only 14% say it is easy to scale one, with 82% negative on tax and 74% finding investment hard to access. On this reading the constraint is regulation and tax, not the capital-vehicle design the state keeps adjusting.
New Economics Foundation
New Economics Foundation
The New Economics Foundation argues fiscal accounting rules, not political will, cap what Britain's state capital vehicles can do. Matching the KfW and Bpifrance benchmark of 1% of GDP would need the National Wealth Fund to deploy roughly GBP21bn a year by 2028-29, about four times its current capacity.
Competition and Markets Authority
Competition and Markets Authority
The CMA's 8 September report on public procurement asked whether Britain's roughly GBP400bn state-spending system is built to grow high-potential firms rather than simply widen SME participation. Its Recommendation 5 calls for a dedicated frontier-technology procurement framework, an official acknowledgement that today's design may serve the wrong target.
Highland Europe
Highland Europe
Highland Europe, the growth-equity firm behind a €1bn-plus fund, took €65m from the British Business Bank into its Technology Growth Fund VI on 30 July via British Patient Capital. For a Geneva-based growth investor, the Bank's cheque is routine cornerstone capital, unrelated to which Whitehall department currently claims to sponsor UKRI.